drugset / Trial / NCT05218668
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Timeline
- Start
- 2021-12-22
- Primary completion
- 2026-07
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fasudil | Small molecule | 180 mg | Oral |
| Subject | Fasudil | Small molecule | 300 mg | Oral |